Research Topics
| J J VredenburghSummaryAffiliation: Duke University Medical Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic supportJ J Vredenburgh
Duke University Bone Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina 27710, USA
Biol Blood Marrow Transplant 3:91-7. 1997..A comparison with other prognostic factors and characteristics of the tumor may determine the significance of the tumor contamination of the bone marrow...- Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotheraJames J Vredenburgh
Duke University Medical Center, Durham, North Carolina 27710, USA
Biol Blood Marrow Transplant 12:195-203. 2006..Salvage HDC converted 30% of partial responders to complete responders with similar survivals. The addition of novel targeted therapies to intensive-dose chemotherapy regimens may further improve survival in metastatic breast cancer... - Phase II trial of bevacizumab and irinotecan in recurrent malignant gliomaJames J Vredenburgh
The Preston Robert Tisch Brain Tumor Center and Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 13:1253-9. 2007..This study was conducted to determine if the combination of a novel antiangiogenic therapy, bevacizumab, and a cytotoxic agent, irinotecan, is safe and effective for patients with recurrent grade III-IV glioma... - Bevacizumab plus irinotecan in recurrent glioblastoma multiformeJames J Vredenburgh
Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 25:4722-9. 2007..We performed a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan... 
Experience with irinotecan for the treatment of malignant gliomaJames J Vredenburgh
The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 11:80-91. 2009..Toxicities associated with irinotecan have been manageable; the most important dose-limiting toxicities are neutropenia and diarrhea. Irinotecan-based chemotherapy of malignant glioma merits further study...- A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only boneJ J Vredenburgh
Division of Medical Oncology Transplantation, Duke University Medical Center, Durham, NC 27710, USA
Bone Marrow Transplant 37:1009-15. 2006.... 
Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiformeJames J Vredenburgh
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Int J Radiat Oncol Biol Phys 82:58-66. 2012..To determine the safety of the addition of bevacizumab to standard radiation therapy and daily temozolomide for newly diagnosed glioblastoma multiforme (GBM)...- Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN studyJames J Vredenburgh
Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC 27710, USA
Oncologist 15:1329-34. 2010..We assessed corticosteroid use in patients with recurrent glioblastoma treated with bevacizumab (BEV) in the BRAIN study (J Clin Oncol 2009;27:4733-4740)... - The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastomaJames J Vredenburgh
Departments of Surgery, Neurology, Pediatrics, Medicine, Radiation Oncology, and Cancer Center Biostatistics, Duke University Medical Center, Durham, North Carolina
Clin Cancer Res 17:4119-24. 2011..To determine if the addition of bevacizumab to radiation therapy and temozolomide, followed by bevacizumab, temozolomide, and irinotecan, for newly diagnosed glioblastoma patients is safe and effective... - Prognostic and predictive factors for patients with metastatic breast cancer undergoing aggressive induction therapy followed by high-dose chemotherapy with autologous stem-cell supportD A Rizzieri
Duke University Medical Center Marrow and Stem Cell Transplantation Program, Durham, NC 27710, USA
J Clin Oncol 17:3064-74. 1999..We performed a retrospective review to determine predictive and prognostic factors in patients with metastatic breast cancer who received induction therapy, and, if they responded to treatment, high-dose chemotherapy... - Impact of consolidation radiotherapy in patients with advanced breast cancer treated with high-dose chemotherapy and autologous bone marrow rescueD L Carter
Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA
J Clin Oncol 17:887-93. 1999..To examine the impact of consolidation radiotherapy (RT) after high-dose chemotherapy with autologous bone marrow rescue (HDC) in patients with advanced breast cancer... - Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapyJennifer A Quinn
Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
J Neurooncol 95:393-400. 2009..The lack of correlation of activity with MGMT expression is intriguing, but needs further evaluation in subsequent trials... - Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patientsD A Reardon
Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, 200 Trent Drive, Durham, NC 27710, USA
Br J Cancer 107:1481-7. 2012..We evaluated bevacizumab continuation beyond initial progression among recurrent glioblastoma patients as it is a common, yet unsupported practice in some countries... - Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplantsMichael A Morse
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
J Hematother Stem Cell Res 11:659-68. 2002.... - Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecanSith Sathornsumetee
Department of Medicine, Duke University Medical Center, DUMC 2900, Durham, NC 27710, USA
J Clin Oncol 26:271-8. 2008.... - Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant gliomaJennifer A Quinn
Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA
Cancer 115:2964-70. 2009..The trial was designed to determine the maximum tolerated dose (MTD) and toxicity of irinotecan (CPT-11) when administered with temozolomide (TMZ) and O(6)-benzylguanine (O(6)-BG)... - Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II studyD A Reardon
Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
Br J Cancer 101:1986-94. 2009..We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial... - Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastomaJohn H Sampson
Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 28:4722-9. 2010..Epidermal growth factor receptor variant III (EGFRvIII) is a constitutively activated and immunogenic mutation not expressed in normal tissues but widely expressed in glioblastoma multiforme (GBM) and other neoplasms... - A change in the apparent diffusion coefficient after treatment with bevacizumab is associated with decreased survival in patients with recurrent glioblastoma multiformeM J Paldino
Department of Radiology, Duke University Medical Center, Durham, NC, USA
Br J Radiol 85:382-9. 2012.... - Inhaled steroids as prophylaxis for delayed pulmonary toxicity syndrome in breast cancer patients undergoing high-dose chemotherapy and autologous stem cell transplantationD S McGaughey
Adult Bone Marrow and Stem Cell Transplant Program, Duke University Medical Center, Durham, North Carolina 27710, USA
Biol Blood Marrow Transplant 7:274-8. 2001..These results are worthy of further study in a randomized clinical trial... - Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapyMary Lou Affronti
Department of Surgery, Duke University Medical Center, and The Preston Robert Tisch Brain Tumor Center, South Hospital, Durham, North Carolina 27710, USA
Cancer 115:3501-11. 2009..The effect of carmustine wafers on the survival of newly diagnosed GBM patients treated with radiotherapy (RT) and concurrent temozolomide (TMZ) plus RT plus rotational chemotherapy was investigated... - Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiformeMichael A Badruddoja
Duke University Medical Center, Brain Tumor Center, Department of Surgery, Durham, NC 27710, USA
Neuro Oncol 9:70-4. 2007..Cloretazine administered every six weeks was relatively well tolerated, although this schedule has insignificant activity for patients with recurrent glioblastoma multiforme... - Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescuePehr A Lind
Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA
Cancer 94:2821-9. 2002..These patients are at risk of developing therapy-related pneumonitis (TRP) during or after radiotherapy (RT)... - Association of high-dose cyclophosphamide, cisplatin, and carmustine pharmacokinetics with survival, toxicity, and dosing weight in patients with primary breast cancerWilliam P Petros
Bone Marrow Transplant Program, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 8:698-705. 2002..Prospective strategies, which attempt to individualize AUC, should be evaluated in this setting... - Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant gliomaJennifer A Quinn
Departments of Surgery, Duke University Medical Center, PO Box 3624, Durham, NC 27710, USA
J Clin Oncol 27:1262-7. 2009.... - Successful allogeneic engraftment of mismatched unrelated cord blood following a nonmyeloablative preparative regimenD A Rizzieri
Marrow and Stem Cell Transplantation Program, Duke University Medical Center, Durham, NC 27710, USA
Blood 98:3486-8. 2001..The patients are in remission and remain 100% donor as assessed by short tandem repeat analysis of the marrow 6 and 12 months following transplantation... - Neurofibromatosis type 2S Sathornsumetee
Preston Robert Tisch Brain Tumor Center, Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Neurology 68:E14. 2007 - Nonmyeloablative regimen preserves "niches" allowing for peripheral expansion of donor T-cellsNelson J Chao
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Biol Blood Marrow Transplant 8:249-56. 2002..Moreover, the presence of TREC-positive cells within 1 year suggests that thymic recovery is likewise accelerated in non myeloablative compared to myeloablative regimens... - Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiformeJennifer A Quinn
Department of Surgery, Pathology, Biostatistics, and Bioinformatics, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 15:1064-8. 2009.... - Posttransplant lymphoproliferative disorder following nonmyeloablative allogeneic stem cell transplantationMatthew J Snyder
Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
Am J Surg Pathol 28:794-800. 2004..All three PTLDs arose 6 to 7 months after NMST and were rapidly fatal. The pathology of the PTLD in all cases was donor origin, EBV positive, diffuse large B-cell lymphoma... - Assessment of physical functioning in recurrent glioma: preliminary comparison of performance status to functional capacity testingLee W Jones
Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
J Neurooncol 94:79-85. 2009..We conducted a pilot study to explore the feasibility and clinical utility of functional capacity testing to assess physical functioning in recurrent primary malignant glioma patients... - Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant gliomaDavid A Reardon
Department of Pediatrics, Duke University Medical Center, Durham, North Carolina, USA
Cancer 115:2188-98. 2009.... - Low-dose weekly paclitaxel for recurrent or refractory aggressive non-Hodgkin lymphomaDavid A Rizzieri
Division of Medical Oncology and Transplantation, Duke University Medical Center, and the Duke Oncology Network, Duke University, Durham, North Carolina 27710, USA
Cancer 100:2408-14. 2004..The current study tested this hypothesis by using low-dose, weekly paclitaxel in patients with recurrent or refractory NHL... - Repeatability of quantitative parameters derived from diffusion tensor imaging in patients with glioblastoma multiformeMichael J Paldino
Duke University Medical Center, Department of Radiology, Durham, North Carolina 27710, USA
J Magn Reson Imaging 29:1199-205. 2009..To quantify the repeatability of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) in patients with glioblastoma multiforme... - Phase II trial of gefitinib in recurrent glioblastomaJeremy N Rich
Duke University Medical Center, Box 2900, Durham, NC 27710, USA
J Clin Oncol 22:133-42. 2004..To evaluate the efficacy and tolerability of gefitinib (ZD1839, Iressa; AstraZeneca, Wilmington, DE), a novel epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma... - Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patientsStephanie L Perry
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
J Neurooncol 95:129-34. 2009..Tinzaparin at a fixed prophylactic dose is safe and may decrease the incidence of thromboembolic complications in brain tumor patients... - Candidemia in women with breast carcinoma treated with high-dose chemotherapy and autologous bone marrow transplantationMagnus Gottfredsson
Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, North Carolina, USA
Cancer 98:24-30. 2003..No systemic antifungal prophylaxis was administered. The purpose of the current study was to evaluate the risk and long-term outcome of candidemia in this patient population... - 4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemiaDavid A Rizzieri
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
Biol Blood Marrow Transplant 9:183-8. 2003..Approaches to minimize stomatitis and protect normal stem cells from the toxicity of 4HC may improve the tolerance and efficacy of this approach... - Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastomaDavid A Reardon
Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA
J Neurooncol 96:219-30. 2010..029). Erlotinib plus sirolimus was well tolerated but had negligible activity among unselected recurrent GBM patients. (ClinicalTrials.gov number: NCT0062243)... - Phase I evaluation of prolonged-infusion gemcitabine with fludarabine for relapsed or refractory acute myelogenous leukemiaDavid A Rizzieri
Duke University Medical Center, Division of Medical Oncology and Transplantation and the Duke Oncology Consortium, Durham, North Carolina 27710, USA
Clin Cancer Res 9:663-8. 2003.... - Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant gliomaJennifer A Quinn
Dept of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC, USA
Neuro Oncol 11:556-61. 2009..This study provides the foundation for a phase II trial of O(6)-BG in combination with a 5-day dosing schedule of TMZ in TMZ-resistant MG... - Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastomaDavid A Reardon
Department of Surgery, Duke University Medical Center, Durham, NC, 27710, USA
J Neurooncol 101:57-66. 2011..In conclusion, sorafenib can be safely administered with daily temozolomide, but this regimen has limited activity for recurrent GBM. Co-administration of EIAEDs can lower sorafenib exposures in this population... - Ulceration of Striae distensae in high-grade glioma patients on concurrent systemic corticosteroid and bevacizumab therapyKatherine B Peters
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, 27710, USA
J Neurooncol 101:155-9. 2011.... - Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemiaSteven L McCune
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA
Leuk Lymphoma 43:1007-11. 2002..Alemtuzumab is a monoclonal antibody that offers effective treatment for chemotherapy refractory CLL and PLL and is generally well tolerated in the outpatient setting... - Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSFCristina Gasparetto
Division of Medical Oncology and Transplantation, Duke University Medical Center, Durham, NC, USA
Cytokine 18:8-19. 2002..In summary, administration of FL in combination with GM-CSF and G-CSF to patients with breast cancer can mobilize large numbers of immature DCs into PBSC leukapheresis collections... - Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomasAnnick Desjardins
Department of Surgery, Duke University Medical Center, Durham, North Carolina 27710, USA
Clin Cancer Res 14:7068-73. 2008..We did a phase II trial of bevacizumab, a monoclonal antibody to vascular endothelial growth factor, in combination with irinotecan for patients with recurrent grade 3 malignant glioma... - Efficacy of high-dose chemotherapy or standard salvage therapy in patients with recurrent medulloblastomaSridharan Gururangan
Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 10:745-51. 2008..The favorable impact of HDC on disease control in the two long-term survivors cannot be clearly established due to the cofounding effect of definitive RT postrecurrence... - Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitutionDavid A Rizzieri
Department of Medicine, Division of Cellular Therapy, Duke University Medical Center, Durham, NC 27710, USA
J Clin Oncol 25:690-7. 2007..To allow a donor to be found for nearly all patients, we have used a nonmyeloablative conditioning regimen in conjunction with stem cells from a related donor with one fully mismatched HLA haplotype... - Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomasAnnick Desjardins
Department of Medicine, Division of Neurology, The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
J Neurooncol 83:53-60. 2007..We performed the current phase 2 study to evaluate this regimen among patients with recurrent WHO grade III malignant glioma (MG)... - Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiformeDavid A Reardon
Department of Medicine, Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA
J Clin Oncol 23:9359-68. 2005.... - Temozolomide in children with progressive low-grade gliomaSridharan Gururangan
Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
Neuro Oncol 9:161-8. 2007..TMZ given in this schedule was successful in stabilizing disease in a significant proportion of the patients with OPG/PA, with manageable toxicity... - Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study resultsDavid A Reardon
Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC, 27710, USA
J Clin Oncol 24:115-22. 2006..To assess the efficacy and toxicity of intraresection cavity iodine-131-labeled murine antitenascin monoclonal antibody 81C6 (131I-m81C6) among recurrent malignant brain tumor patients... - Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial resultsDavid A Reardon
Department of Surgery, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina, USA
J Nucl Med 47:912-8. 2006.... - Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant gliomaDavid A Reardon
AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
Clin Cancer Res 12:860-8. 2006.... - The emerging role of anti-angiogenic therapy for malignant gliomaDavid A Reardon
Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
Curr Treat Options Oncol 9:1-22. 2008..Promising results of these approaches suggest that the treatment of GBM may represent an emerging paradigm of anti-angiogenic therapy... - A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boostDavid A Reardon
Department of Surgery, Division of Neurosurgery, Duke University Medical Center, Durham, NC 27710, USA
Neuro Oncol 10:182-9. 2008..S. Food and Drug Administration has approved a trial randomizing newly diagnosed GBM patients to either our study regimen or standard XRT plus temozolomide... - Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapyDavid A Reardon
Duke University Medical Center, Neuro Oncology Program, Department of Surgery, Division of Neurosurgery, 047 Baker House, Box 3624, Durham, North Carolina 27710, USA
Expert Opin Biol Ther 8:541-53. 2008..Malignant gliomas are amongst the most angiogenic of cancers, and VEGF is the dominant angiogenic mediator in these tumors... - Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant gliomaRichard G Everson
Division of Neurosurgery, Department of Surgery, Box 3050 Med Ctr, Preston Robert Tisch Brain Tumor Center at Duke University, Durham, NC 27710, USA
Expert Rev Anticancer Ther 8:717-32. 2008.... - Cryptococcal meningitis in patients with glioma: a report of two casesJonathan D Choi
Division of Neurosurgery, Department of Surgery, Duke University School of Medicine, Durham, NC 27705, USA
J Neurooncol 89:51-3. 2008..This report of two cases highlights the importance of examining the efficacy of prophylactic antibiotic and/or antifungal regimens in this patient population due to their increased risk of opportunistic infections... - Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant gliomaDavid A Reardon
Department of Surgery, Duke University Medical Center, Box 3624, Durham, NC 27710, USA
Neuro Oncol 10:330-40. 2008..A subsequent phase 2 study is required to further evaluate the efficacy of this regimen for this patient population... - Bevacizumab fails to treat temporal paraganglioma: discussion and case illustrationHamidreza Aliabadi
Department of Surgery, Division of Neurosurgery, Duke University Medical Center, 220 Sands Building, Research Drive, Box 3050, Durham, NC 27710, USA
J Neurooncol 98:427-30. 2010..This patient was treated with bevacizumab prior to surgical treatment; radiographic imaging at 3 months, however, showed no significant response. We discuss possible reasons for treatment failure... - Fatal re-expansion pulmonary edema associated with increased lung IL-8 levels following high-dose chemotherapy and autologous stem cell transplantStavros Garantziotis
Division of Pulmonary and Critical Care Medicine, Duke University Medical Center, Durham, NC 27710, USA
Respiration 69:351-4. 2002..This suggests that patients who have recently undergone HDC/ASCT may be at increased risk for the development of REPE following thoracentesis... - Molecularly targeted therapy for malignant gliomaSith Sathornsumetee
The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
Cancer 110:13-24. 2007..In this review, the authors discussed the current understanding of molecular pathogenesis and the development of molecularly targeted therapies in malignant glioma... - Pulmonary sarcoidosis following stem cell transplantation: is it more than a chance occurrence?Rajesh Bhagat
Division of Pulmonary, Allergy, and Critical Care Medicine, Duke University Medical Center, Durham, NC 27710, USA
Chest 126:642-4. 2004..We suggest that pulmonary sarcoidosis may develop following either autologous or allogeneic HSCT, and the prevalence may be 10-fold higher than that of the normal population... - Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomitingEyal Meiri
Bethesda Memorial Hospital, Comprehensive Cancer Care Center, Boynton Beach, FL 33435 7995, USA
Curr Med Res Opin 23:533-43. 2007..To compare the efficacy and tolerability of dronabinol, ondansetron, or the combination for delayed chemotherapy-induced nausea and vomiting (CINV) in a 5-day, double-blind, placebo-controlled study... - Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancerWilliam P Petros
West Virginia University Health Sciences Center, PO Box 9300, Morgantown, WV 26506, USA
J Clin Oncol 23:6117-25. 2005..To evaluate associations between patient survival, pharmacokinetics, and drug metabolism-related genetic polymorphisms in patients receiving a combination chemotherapy regimen for breast cancer... - Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MAWilliam P Peters
Cancer and Leukemia Group B, 230 W Monroe St, Suite 2050, Chicago, IL 60606, USA
J Clin Oncol 23:2191-200. 2005..75). CONCLUSION: HD-CPB with stem-cell support was not superior to ID-CPB for event-free or overall survival among all randomized women with high-risk primary breast cancer... - Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancerYago Nieto
Bone Marrow Transplant Program and Department of Biostatistics, University of Colorado Health Sciences Center, Denver, Colorado, USA
Clin Cancer Res 10:7136-43. 2004.... - High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodesMonic J Stuart
Division of Bone Marrow Transplantation, Stanford University Medical Center, Stanford, California, USA
Biol Blood Marrow Transplant 8:666-73. 2002..Our study presents long-term favorable results regarding the use of consolidative HDC with autologous hematopoietic support in previously untreated patients with high-risk primary breast cancer... - Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic miceMichael A Badruddoja
Center for Neurosciences, University of Arizona, Tucson, AZ 85721, USA
Neuro Oncol 9:240-4. 2007..001), with one toxic death. These findings suggest that VNP40101M is active in the treatment of a wide range of human central nervous system tumors and warrants translation to the clinic...